Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Valle

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Journal of Cancer|March 10, 2016
Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer PatientsPatrizia Vici, Laura Pizzuti, Luigi Di Lauro, et al.
Journal of Cellular Physiology|May 26, 2017
GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancerLaura Pizzuti, Domenico Sergi, Chiara Mandoj, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 6, 2024
Enhanced recovery after surgery (ERAS) implementation in cytoreductive surgery (CRS) and hyperthermic IntraPEritoneal chemotherapy (HIPEC): Insights from Italian peritoneal surface malignancies expert centersManuela Robella, Marco Vaira, Luca Ansaloni, et al.
Annals of Surgical Oncology|November 16, 2021
Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)Marco Tonello, Dario Baratti, Paolo Sammartino, et al.
Annals of Surgical Oncology|April 6, 2022
Correction: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)Marco Tonello, Dario Baratti, Paolo Sammartino, et al.
Annals of Surgical Oncology|October 13, 2023
Is Systemic Chemotherapy Useful in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases? A Propensity-Score AnalysisMarco Tonello, Dario Baratti, Paolo Sammartino, et al.
Tumori|April 22, 2017
1st Evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancerDavide Cavaliere, Roberto Cirocchi, Federico Coccolini, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 29, 2020
Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastasesDario Baratti, Paolo Sammartino, Shigeki Kusamura, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Journal of Cancer|March 10, 2016
Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer PatientsPatrizia Vici, Laura Pizzuti, Luigi Di Lauro, et al.
Journal of Cellular Physiology|May 26, 2017
GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancerLaura Pizzuti, Domenico Sergi, Chiara Mandoj, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 6, 2024
Enhanced recovery after surgery (ERAS) implementation in cytoreductive surgery (CRS) and hyperthermic IntraPEritoneal chemotherapy (HIPEC): Insights from Italian peritoneal surface malignancies expert centersManuela Robella, Marco Vaira, Luca Ansaloni, et al.
Annals of Surgical Oncology|November 16, 2021
Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)Marco Tonello, Dario Baratti, Paolo Sammartino, et al.
Annals of Surgical Oncology|April 6, 2022
Correction: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)Marco Tonello, Dario Baratti, Paolo Sammartino, et al.
Annals of Surgical Oncology|October 13, 2023
Is Systemic Chemotherapy Useful in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases? A Propensity-Score AnalysisMarco Tonello, Dario Baratti, Paolo Sammartino, et al.
Tumori|April 22, 2017
1st Evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancerDavide Cavaliere, Roberto Cirocchi, Federico Coccolini, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 29, 2020
Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastasesDario Baratti, Paolo Sammartino, Shigeki Kusamura, et al.
Pageof 8